Q3 revenue grew 11.97% year-over-year, with net profit up 176.18% and strong cash flow. Cardiovascular and formulation sales led growth, while forex losses and investment losses increased. Major product approvals and a share buyback cancellation marked the quarter.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.